ELARA trial, follicular lymphoma, Kymriah, NCT03568461, Novartis, Novartis Pharmaceuticals Corporation, Tisagenlecleucel
Tisagenlecleucel is approved by FDA for relapsed or refractory follicular lymphoma
June 2022: After two or more lines of systemic therapy, the FDA awarded tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) expedited approval for adult patients with relapsed or refractory follicular lymphoma (FL).T..
cytokine release syndrome, Jill O’Donnell-Tormey, Kymriah, Novartis
CAR-T Cell therapy could be made safer and more widely available with a few adjustments
March 2022: A revolutionary approach to CAR-T Cell therapy has the potential to overturn what has become a medical axiom: that the treatment's remarkable effect on tumours comes at the expense of substantial hazards to patient saf..
Kite, Kymriah, Novartis, Yeskarta
CAR NK therapy has an effective rate of 73%
Immunotherapy in treatment of cancerCancer CAR-NK therapy has an effective rate of 73%, and is being recruited in domestic clinical trials.Immunotherapy has revolutionized the way cancer is treated. Cancer immunotherapy is divide..
Acalabrutunib, Avelumab, CART therapy, Dabrafanib, Kymriah, Latest drugs, Midostaurin, Niraparib, Pembrolizumab, Tecartus, Tisagenlecleucel, Trametinib, USFDA
Latest drugs in the treatment of cancer
July 2021: Check out the latest drugs in the treatment of cancer. Every year, after examining the trials and other important factors, the USFDA approves drugs, and thus cancer patients can now believe that a cure is very near. ..